Pasithea Therapeutics Company Insiders

KTTA Stock  USD 2.54  0.12  4.51%   
Pasithea Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Pasithea Therapeutics Corp suggests that vertually all insiders are extremely bullish. Pasithea Therapeutics employs about 8 people. The company is managed by 7 executives with a total tenure of roughly 19 years, averaging almost 2.0 years of service per executive, having 1.14 employees per reported executive.

Pasithea Therapeutics' Insider Buying Vs Selling

100

 
Selling
 
Buying

Latest Trades

2023-06-02Lawrence SteinmanAcquired 1500 @ 8.6View
2022-10-17David DelaneyAcquired 50 @ 22.2View
2022-09-28Eric ShahinianAcquired 2882 @ 23.8View
2022-08-29Eric ShahinianAcquired 250 @ 23.4View
2022-08-19Avi GellerAcquired 2732 @ 26View
2022-08-17Eric ShahinianAcquired 7788 @ 24.2View
Monitoring Pasithea Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Pasithea Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.379) % which means that it has lost $0.379 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6325) %, meaning that it created substantial loss on money invested by shareholders. Pasithea Therapeutics' management efficiency ratios could be used to measure how well Pasithea Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.9. In addition to that, Return On Capital Employed is expected to decline to -0.71. At present, Pasithea Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 62.1 M, whereas Non Current Assets Total are forecasted to decline to about 5.7 M.
As of December 19, 2024, Common Stock Shares Outstanding is expected to decline to about 1.2 M. The current year's Net Loss is expected to grow to about (1.9 M)

Pasithea Therapeutics Workforce Comparison

Pasithea Therapeutics Corp is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 311. Pasithea Therapeutics holds roughly 8.0 in number of employees claiming about 2.57% of equities under Health Care industry.

Pasithea Therapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pasithea Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pasithea Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pasithea Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Pasithea Therapeutics Notable Stakeholders

A Pasithea Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pasithea Therapeutics often face trade-offs trying to please all of them. Pasithea Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pasithea Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
BA MDExecutive CoFounderProfile
Tiago MDCEO DirectorProfile
Yassine BendiabdallahCOO ClinicsProfile
MD BAEx CoFounderProfile
Tiago MarquesCEO DirectorProfile
Daniel SchneidermanChief OfficerProfile
Graeme CurrieChief OfficerProfile

About Pasithea Therapeutics Management Performance

The success or failure of an entity such as Pasithea Therapeutics often depends on how effective the management is. Pasithea Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pasithea management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pasithea management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.94)(0.90)
Return On Capital Employed(0.68)(0.71)
Return On Assets(0.61)(0.64)
Return On Equity(0.68)(0.65)
Please note, the presentation of Pasithea Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pasithea Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Pasithea Therapeutics' management manipulating its earnings.

Pasithea Therapeutics Workforce Analysis

Traditionally, organizations such as Pasithea Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pasithea Therapeutics within its industry.

Pasithea Therapeutics Manpower Efficiency

Return on Pasithea Therapeutics Manpower

Revenue Per Employee60.8K
Revenue Per Executive69.5K
Net Loss Per Employee1.9M
Net Loss Per Executive2.2M
Working Capital Per Employee1.8M
Working Capital Per Executive2M

Complementary Tools for Pasithea Stock analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Content Syndication
Quickly integrate customizable finance content to your own investment portal
CEOs Directory
Screen CEOs from public companies around the world
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities